Adaptive Biotechnologies (ADPT) Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADPT, but not buy additional shares or sell existing shares.
View ADPT analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month price targets for Adaptive Biotechnologies' shares. Their ADPT share price forecasts range from $7.00 to $17.00. On average, they anticipate the company's stock price to reach $13.80 in the next year. This suggests a possible upside of 95.7% from the stock's current price.
View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts.

Adaptive Biotechnologies' stock was trading at $7.64 on January 1st, 2023. Since then, ADPT stock has decreased by 7.7% and is now trading at $7.05.
View the best growth stocks for 2023 here.

Adaptive Biotechnologies saw a increase in short interest in May. As of May 15th, there was short interest totaling 6,630,000 shares, an increase of 8.9% from the April 30th total of 6,090,000 shares. Based on an average daily volume of 856,600 shares, the short-interest ratio is presently 7.7 days. Currently, 4.8% of the shares of the stock are sold short.
View Adaptive Biotechnologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our ADPT earnings forecast.

Adaptive Biotechnologies Co. (NASDAQ:ADPT) released its earnings results on Wednesday, May, 3rd. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.06. The firm earned $37.65 million during the quarter, compared to analysts' expectations of $36.81 million. Adaptive Biotechnologies had a negative trailing twelve-month return on equity of 41.21% and a negative net margin of 105.87%. The business's quarterly revenue was down 2.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.44) EPS.

ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), ETFMG Treatments Testing and Advancements ETF (GERM), Invesco Nasdaq Future Gen 200 ETF (QQQS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB).

Adaptive Biotechnologies issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $205.00 million-$215.00 million, compared to the consensus revenue estimate of $208.52 million.

51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

(ADPT) raised $200 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol "ADPT."

Adaptive Biotechnologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.15%), ARK Investment Management LLC (6.43%), Sumitomo Mitsui Trust Holdings Inc. (3.72%), Nikko Asset Management Americas Inc. (3.72%), State Street Corp (1.78%) and Geode Capital Management LLC (1.54%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Charles Sang, David E Goel, Egon Durban, Eric Dobmeier, Euclidean Capital Llc, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michael J Pellini, Michelle Renee Griffin, Nancy Louise Hill, Nitin Sood, R Mark Adams, Robert Hershberg, Sharon Benzeno, Stacy L Taylor and Susan Bobulsky.
View institutional ownership trends.

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADPT stock can currently be purchased for approximately $7.05.

Adaptive Biotechnologies (NASDAQ:ADPT) has a market capitalization of $1.02 billion and generates $185.31 million in revenue each year. The company earns $-200,190,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

The company employs 858 workers across the globe.

Adaptive Biotechnologies' mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The official website for the company is www.constructionpartners.net. The company can be reached via phone at (206) 659-0067, via email at investors@adaptivebiotech.com, or via fax at 206-659-0667.